Merck Reports Phase 2b Data for Ibrutinib in Psoriatic arthritis

Merck today announced Phase 2b results for ibrutinib in patients with psoriatic arthritis. The study demonstrated that ibrutinib achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of psoriatic arthritis and support the continued development of ibrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.